In 1869, Swiss scientist Friedrich Miescher isolated a mysterious substance from cell nuclei—an overlooked finding that would ...

A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

Understanding the stages of Merkel cell carcinoma (MCC) helps you and your physician know how far the cancer has grown or spread. These stages also guide decisions about the treatment options your ...

Patients with resected Merkel cell carcinoma (MCC) living in Medicaid expansion states showed higher 5-year overall survival than those in nonexpansion states, despite having more adverse tumor ...

As people age, their immune system function declines. T cell populations become smaller and can't react to pathogens as quickly, making people more susceptible to a variety of infections. To try to ...

Background: Merkel cell carcinoma (MCC) of the eyelid is rare and aggressive. Diagnostic delay and inadequate excision may promote early nodal spread. We assessed the influence of surgical margins and ...

One of the main changes is a loss of the innate immune system's naive T cells, the first line of defense against pathogens, and an increase in the adaptive immune system's memory T cells. This ...

Please provide your email address to receive an email when new articles are posted on . A one-time infusion of BMS-986353, a CD19 CAR T-cell therapy, improved lung function and skin thickness.

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's immune system to target and eliminate cancer cells appeared to reduce the ...

Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients with Merkel cell carcinoma after surgery. Though recurrence rates overall ...